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There is a lack of knowledge about neuroprotective factors in diabetes mellitus. Heat shock protein 27 (HSP27) acts as a filament stabilizer and inhibits apoptotic pathways (1) . Thus, HSP27 may be important as a neuroprotective factor (2) . Our aims were to study whether HSP27 concentrations differ between individuals with and without type 1 diabetes, and to evaluate the relationship between progression of neuropathy and HSP27 concentration. At baseline, type 1 diabetes patients were in their middle-age, and had more than 20 years duration of the disease (Table 1 ). Their glucose control was acceptable, and the weight and blood pressure was close to normal. Few of them had anti-hypertensive or lipid lowering medication. There were no major changes in body weight, systolic blood pressure, HbA1c, and HSP27 concentrations from baseline to follow-up (Table 1) . Type 1 diabetes patients had lower HSP27 concentrations at baseline (geometric mean HSP27 547 pg/ml, 95% CI 421, 711) and at follow-up (geometric mean HSP27 538 pg/ml, 95% CI 417, 693) compared to healthy controls (geometric mean HSP27 785 pg/ml, 95% CI 732, 842;
p<0.05 for both comparisons). Progression of large nerve fibre dysfunction correlated with a relative decrease in HSP27 concentrations during the follow-up period (r s =0.50, p=0.01).
We report that patients with type 1 diabetes had lower HSP27 concentrations than nondiabetic healthy controls. The correlation between progression of large nerve fibre dysfunction and a relative decrease in serum HSP27 concentrations during the follow-up period could be indicative of an association between neuropathy and HSP27. One study showed higher HSP27 concentrations in T1DM patients with neuropathy than in T1DM patients without neuropathy (3) . Our diverging finding could be due to different assessment of nerve function, different study design and choice of controls. HSP27 could be related to other diseases than diabetes, and not necessarily related to peripheral nerves (4). However, we found no association between HSP27 and factors, such as antihypertensive medication, lipids, blood pressure and BMI. It has been shown in animal models that experimental up-regulation of HSP27 is related to neuronal protection (5) . This neuroprotective role has further been suggested in animal models, where experimental overexpression of HSP27 prior to diabetes resulted in protection from a range of sensory abnormalities (2) . Regardless of the mechanism behind our findings, HSP27 might play a neuroprotective role in humans. Our results suggest an insufficient neuroprotection in type 1 diabetes patients. The authors declare that there is no duality of interest associated with this manuscript. 
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